NO20061320L - Kinazolinderivater som antitumor agenter - Google Patents
Kinazolinderivater som antitumor agenterInfo
- Publication number
- NO20061320L NO20061320L NO20061320A NO20061320A NO20061320L NO 20061320 L NO20061320 L NO 20061320L NO 20061320 A NO20061320 A NO 20061320A NO 20061320 A NO20061320 A NO 20061320A NO 20061320 L NO20061320 L NO 20061320L
- Authority
- NO
- Norway
- Prior art keywords
- antitumor agents
- chinazoline derivatives
- chinazoline
- derivatives
- effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Kinazolinderivat med formel I: hvor substituentene er som definert i teksten for anvendelse ved fremstilling av en anti-proliferativ effekt, idet denne effekten blir frembragt helt eller delvis ved å hemme erbB2-reseptor-tyrosinkinase hos et varmblodig dyr, så som mennesket.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321648.8A GB0321648D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
PCT/GB2004/003936 WO2005026152A1 (en) | 2003-09-16 | 2004-09-14 | Quinazoline derivatives as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061320L true NO20061320L (no) | 2006-04-26 |
Family
ID=29227164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061320A NO20061320L (no) | 2003-09-16 | 2006-03-23 | Kinazolinderivater som antitumor agenter |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070015743A1 (no) |
EP (1) | EP1664029B1 (no) |
JP (1) | JP2007505874A (no) |
CN (1) | CN1882572A (no) |
AR (1) | AR045752A1 (no) |
AT (1) | ATE450528T1 (no) |
AU (1) | AU2004272351A1 (no) |
BR (1) | BRPI0414486A (no) |
CA (1) | CA2539024A1 (no) |
DE (1) | DE602004024420D1 (no) |
GB (1) | GB0321648D0 (no) |
IL (1) | IL174260A0 (no) |
MX (1) | MXPA06002965A (no) |
NO (1) | NO20061320L (no) |
TW (1) | TW200526628A (no) |
WO (1) | WO2005026152A1 (no) |
ZA (1) | ZA200602189B (no) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050042055A (ko) * | 2001-11-03 | 2005-05-04 | 아스트라제네카 아베 | 항종양제로서의 퀴나졸린 유도체 |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
WO2005026151A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
ATE395346T1 (de) * | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
AU2004272345A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
CN1914182B (zh) * | 2004-02-03 | 2011-09-07 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
NZ562109A (en) * | 2005-06-16 | 2011-03-31 | Myrexis Inc | Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same |
DE602006018331D1 (de) * | 2005-09-20 | 2010-12-30 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
EP1940825A1 (en) * | 2005-09-20 | 2008-07-09 | Astra Zeneca AB | Quinazoline derivatives as anticancer agents |
PL1971601T3 (pl) | 2005-11-15 | 2010-03-31 | Array Biopharma Inc | Pochodne N4-fenylo-chinazolino-4-aminy i związki pokrewne jako inhibitory receptorowych kinaz tyrozynowych ErbB typu I do leczenia chorób cechujących się nadmierną proliferacją komórek |
JP2009517450A (ja) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体 |
CN101321739A (zh) * | 2005-12-02 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物 |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
WO2008095847A1 (de) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
AU2008236994A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating melanoma |
NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
KR20100016385A (ko) * | 2007-04-10 | 2010-02-12 | 미리어드 파마슈티칼스, 인코포레이티드 | 뇌종양 치료방법 |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
WO2008124826A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating cancer |
EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
JP5739802B2 (ja) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩 |
EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
SI2765990T1 (sl) | 2011-10-14 | 2017-11-30 | Array Biopharma, Inc. | Trdna disperzija |
CA2852060A1 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them |
TW202344253A (zh) * | 2018-05-08 | 2023-11-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE291897T1 (de) * | 1996-01-31 | 2005-04-15 | Cosmoferm Bv | Verwendung von zusammensetzungen mit stabilisierten enzymen |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6148197A (en) * | 1998-03-06 | 2000-11-14 | Sbc Technology Resources, Inc. | Intelligent roaming system with over the air programming |
US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
EE200100449A (et) * | 1999-02-27 | 2002-12-16 | Boehringer Ingelheim Pharma Kg | 4-aminokinasoliini ja kinoliini derivaadid inhibeeriva toimega türosiinkinaaside vahendatud signaali ülekandele |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
KR20050042055A (ko) * | 2001-11-03 | 2005-05-04 | 아스트라제네카 아베 | 항종양제로서의 퀴나졸린 유도체 |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
EP1667996B1 (en) * | 2003-09-16 | 2009-07-22 | Astrazeneca AB | Quinazoline derivatives |
WO2005026151A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
ATE395346T1 (de) * | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
US20070037837A1 (en) * | 2003-09-19 | 2007-02-15 | Hennequin Laurent Francois A | Quinazoline derivatives |
JP2007506716A (ja) * | 2003-09-25 | 2007-03-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
CN1914182B (zh) * | 2004-02-03 | 2011-09-07 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
-
2003
- 2003-09-16 GB GBGB0321648.8A patent/GB0321648D0/en not_active Ceased
-
2004
- 2004-09-14 AT AT04768482T patent/ATE450528T1/de not_active IP Right Cessation
- 2004-09-14 MX MXPA06002965A patent/MXPA06002965A/es unknown
- 2004-09-14 BR BRPI0414486-4A patent/BRPI0414486A/pt not_active Application Discontinuation
- 2004-09-14 EP EP04768482A patent/EP1664029B1/en not_active Expired - Lifetime
- 2004-09-14 JP JP2006526685A patent/JP2007505874A/ja active Pending
- 2004-09-14 AU AU2004272351A patent/AU2004272351A1/en not_active Abandoned
- 2004-09-14 CA CA002539024A patent/CA2539024A1/en not_active Abandoned
- 2004-09-14 CN CNA2004800335283A patent/CN1882572A/zh active Pending
- 2004-09-14 WO PCT/GB2004/003936 patent/WO2005026152A1/en active Application Filing
- 2004-09-14 DE DE602004024420T patent/DE602004024420D1/de not_active Expired - Lifetime
- 2004-09-14 US US10/572,262 patent/US20070015743A1/en not_active Abandoned
- 2004-09-16 AR ARP040103319A patent/AR045752A1/es unknown
- 2004-09-16 TW TW093128079A patent/TW200526628A/zh unknown
-
2006
- 2006-03-12 IL IL174260A patent/IL174260A0/en unknown
- 2006-03-15 ZA ZA200602189A patent/ZA200602189B/en unknown
- 2006-03-23 NO NO20061320A patent/NO20061320L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200526628A (en) | 2005-08-16 |
JP2007505874A (ja) | 2007-03-15 |
CA2539024A1 (en) | 2005-03-24 |
BRPI0414486A (pt) | 2006-11-14 |
AR045752A1 (es) | 2005-11-09 |
WO2005026152A1 (en) | 2005-03-24 |
IL174260A0 (en) | 2006-08-01 |
US20070015743A1 (en) | 2007-01-18 |
MXPA06002965A (es) | 2006-06-14 |
ZA200602189B (en) | 2007-11-28 |
ATE450528T1 (de) | 2009-12-15 |
EP1664029A1 (en) | 2006-06-07 |
EP1664029B1 (en) | 2009-12-02 |
CN1882572A (zh) | 2006-12-20 |
AU2004272351A1 (en) | 2005-03-24 |
DE602004024420D1 (de) | 2010-01-14 |
GB0321648D0 (en) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061320L (no) | Kinazolinderivater som antitumor agenter | |
NO20061321L (no) | Kinazolinderivater som tyrosin kinase inhibitorer | |
NO20062353L (no) | Kinazolinderivater | |
NO20054856L (no) | 4-anilino-kinazolinderivater som antiproliferative midler | |
NO20054082L (no) | Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander | |
RS20050441A (en) | C-6 modified indazolylpyrroltriazines | |
WO2007059257A8 (en) | N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
GB0508717D0 (en) | Chemical compounds | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
ATE482212T1 (de) | Pyrrolotriazinverbindungen | |
TW200728277A (en) | Bicyclic derivatives as P38 inhibitors | |
BR0313330A (pt) | Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4 | |
RS53599B1 (en) | PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS | |
BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
MX2007001289A (es) | Piridinas condensadas como inhibidores de cinasa. | |
ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
ATE516291T1 (de) | Thenopyrimidin-verbindungen mit fungizider aktivität | |
BRPI0509731A (pt) | pirazol[4,3-d]pirimidinas | |
MXPA05013149A (es) | Derivados de imidazol como antagonistas del receptor de glutamato. | |
GB0508715D0 (en) | Chemical compounds | |
EA200601176A1 (ru) | 3-цианохинолиновые производные с антипролиферативной активностью | |
TW200745090A (en) | Chemical compounds | |
EP1838712B8 (en) | Pyrazolopyrimidine compounds as antitumor agents | |
WO2005021510A3 (en) | Benzimidazole c-2 heterocycles as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |